14 registrations that name L-arginine as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 14 registrations
Status
Phase
6US sites across 3 states
1
2 to 4
5 to 19
20 or more
All 14 registrations
RecruitingNCT02447874
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
Phase 1 and 2
Emory University
About 21 people
Started May 2015
In plain words A Phase 1 and 2 study of L-arginine in people 7 to 21, run by Emory University. It plans to enroll about 21 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 7 to 21. Conditions: Sickle Cell Disease.
Established diagnosis of sickle cell disease--Hemoglobin SS (Hb-SS) or Sβᴼ-thalassemia
7-21 years of age
Weight >= 25kg (55lbs)
Pain requiring medical care in an acute care setting (emergency department (ED), hospital ward, day hospital, clinic) requiring parenteral opioids, not attributable to non-sickle cell causes.
The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.
Where, as registered
2 US sites in 1 state.
RecruitingNCT07167693
Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes
Phase 1 and 2
David K Carroll
About 60 people
Started Dec 19, 2025
In plain words A Phase 1 and 2 study of L-arginine in people 18 and older, run by David K Carroll. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Diabetes (DM); Diabetic Ketoacidosis; Ketosis Prone Diabetes; Hyperglycaemia (Diabetic).
Age >17 years.
Unscheduled presentation to a participating emergency department with hyperglycemia (serum glucose >250 mg/dL) and significant ketonemia consistent with DKA, defined as laboratory serum/plasma β-hydroxybutyrate (BHB) >20 mg/dL (≈≥1.9…
Clinical phenotype consistent with ketosis-prone type 2 diabetes (no known prior diagnosis of type 1 diabetes).
Able to provide written informed consent and comply with study procedures in the ED.
The exclusion criteria are on the listing.
What it tests, as registered
Arginine hydrochloride; Sodium Chloride 0.9%
Registered summary
Diabetic ketoacidosis (DKA) is increasingly recognized in adults with "ketone-prone" type 2 diabetes. In many of these patients, the pancreas can still make insulin but becomes temporarily "stunned" during severe, prolonged high blood sugar. Arginine is a naturally occurring amino acid that can trigger the pancreas to release its own insulin when glucose is high. It is FDA-approved for other uses and has been given intravenously for decades with a strong safety record. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT03446456
Vasopressin and Pain Perception in the Brain
Phase 1 and 2
University of Maryland, Baltimore
About 56 people
Started Sep 17, 2018
In plain words A Phase 1 and 2 study of L-arginine in people 18 to 65, run by University of Maryland, Baltimore. It plans to enroll about 56 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Acute Pain.
Age ( 18-55 years old)
English speaker (written and spoken)
The exclusion criteria are on the listing.
What it tests, as registered
Arginine vasopressin; Saline; Observational learning; fMRI data aquisition
Registered summary
The feeling of pain is not just a sensory experience, but is also influenced by emotions, beliefs and expectations, making pain a highly subjective experience. This is evident in clinical practice, where the behavior of the physician and the treatment context can strongly influence the pain experience of patients. Research has shown that patients' expectation that a treatment will reduce pain influences individual perception of pain, even if the treatment has no active ingredient. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05855330
Arginine Replacement Therapy in COVID-19
Phase 2
Emory University
About 21 people
Started Jan 8, 2024
In plain words A Phase 2 study of L-arginine in people 3 to 21, run by Emory University. It plans to enroll about 21 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 3 to 21. Conditions: COVID-19.
Established diagnosis of COVID-19 requiring admission to the hospital for treatment of COVID-19 infection
Age 3 years - 21 years of age
The exclusion criteria are on the listing.
What it tests, as registered
Arginine Hydrochloride
Registered summary
This study aims to investigate if receiving doses of arginine (a protein in the body) will improve mitochondria function in children with COVID-19. The study will be performed at the Children's Healthcare of Atlanta, Arthur M. Blank Hospital. Patients will be randomized to receive one of three doses of arginine three times a day for five days or at discharge whichever comes first.
Where, as registered
1 US site in 1 state.
RecruitingNCT06328686
Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases
Early phase 1
Emory University
About 10 people
Started Sep 5, 2024
In plain words An early phase 1 study of L-arginine in people 18 and older, run by Emory University. It plans to enroll about 10 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Solid Neoplasm.
Diagnosis of brain metastases from any primary cancer
Planned to undergo whole-brain radiation therapy (Hippocampal avoidant is ok)
No systemic anti-neoplastic agent concurrent with WBRT (memantine is ok)
Not inpatient at the time of treatment start
2 more inclusion criteria and the exclusion criteria are on the listing.
This early phase I trial evaluates different administration techniques (oral or intravenous) for arginine and tests the safety of giving arginine with whole brain radiation therapy in patients who have cancer that has spread from where it first started (primary site) to the brain (brain metastases). Arginine is an essential amino acid. Amino acids are the molecules that join together to form proteins in the body. Arginine supplementation has been shown to improve how brain metastases respond to radiation therapy. The optimal dosing of arginine for this purpose has not been determined. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06054633
L-arginine for Knee Osteoarthritis Patients
No phase
Xiangya Hospital of Central South University
About 340 people
Started Mar 20, 2024
In plain words A study of L-arginine in people 40 to 80, run by Xiangya Hospital of Central South University. It plans to enroll about 340 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 80. Conditions: Osteoarthritis, Knee.
Age between 40 and 80 years.
Knee OA according to the American College of Rheumatology (ACR) clinical criteria.
Knee pain lasting 3 months or longer and a score of 7 or greater on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale (standardized to range from 0-20).
Kellgren-Lawrence (KL) grade 2 or 3.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
L-arginine tablet; Placebo tablet
Registered summary
This study will examine the pain-relief efficacy and safety of L-arginine in knee OA patients.
Where, as registered
No US site; China (1).
RecruitingNCT06344442
Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)
Phase 3
Assistance Publique - Hôpitaux de Paris
About 304 people
Started Apr 16, 2025
In plain words A Phase 3 study of L-arginine in people 18 and older, run by Assistance Publique - Hôpitaux de Paris. It plans to enroll about 304 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Acute Kidney Injury Post Liver Transplantation.
Age ≥ 18 years
Any adult patient with a scheduled liver transplantation
All participants will need to be given clear information about the study and give signed informed consent.
Person affiliated to the Social Security
The exclusion criteria are on the listing.
What it tests, as registered
Arginine vasopressin; Norepinephrine
Registered summary
Liver transplantation (LT) is a high-risk surgery for hemodynamic instability and haemorrhagic shock with a high-risk of acute kidney injury (AKI). Indeed, the incidence of post-transplant AKI exceeds 50% in some series with 15% of patients requiring renal replacement therapy. Acute kidney injury after LT is a predisposing factor for chronic renal failure which is independently associated with higher morbidity and mortality. Arginine vasopressin (AVP), an essential stress hormone released in response to hypotension, binds to AVPR1a to promote vasoconstriction. The full summary is on the listing.
Where, as registered
No US site; France (1).
RecruitingNCT06483737
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
No phase
General Hospital of Shenyang Military Region
About 174 people
Started Jun 24, 2025
In plain words A study of L-arginine in people 18 and older, run by General Hospital of Shenyang Military Region. It plans to enroll about 174 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Overt Hepatic Encephalopathy.
A definite diagnosis of liver cirrhosis and overt HE
A serum albumin level of 23-30g/L
Age ≥18 years old
Sign the informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Human albumin infusion at a modified dosage; Human albumin infusion at a routine dosage; Lactulose; Rifaximin; Ornithine Aspartate; Branched-Chain Amino Acids; Arginine
Registered summary
Hepatic encephalopathy (HE), a severe complication of decompensated cirrhosis, is characterized as neurocognitive dysfunction. Emerging evidence suggests the potential role of human albumin infusion for the treatment of HE, but its optimal dosage remains undefined. Therefore, the investigators planned a randomized controlled trial (RCT) to compare the efficacy of human albumin infusion at different dosages in in patients with liver cirrhosis and overt HE.
Where, as registered
No US site; China (1).
RecruitingNCT07838493
Oromucosal Oxytocin and Vasopressin Modulation of Emotional Face Attention
No phase
University of Electronic Science and Technology of China
About 120 people
Starts Sep 18, 2026 (estimated)
In plain words A study of L-arginine in people 18 to 30, run by University of Electronic Science and Technology of China. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 30; healthy volunteers accepted. Conditions: Healhty.
Healthy subjects without past or current psychiatric or neurological disorders
Normal or corrected-to-normal vision
Eligible for MRI scanning and willing to undergo blood sampling and study treatment administration
For naturally cycling female participants, willingness and ability to complete the experimental session within the predefined menstrual-cycle phase, determined using menstrual history and urinary luteinizing hormone (LH) testing
1 more inclusion criterion and the exclusion criteria are on the listing.
The goal of this clinical trial is to learn how 24 IU oxytocin (OT) and 24 IU arginine vasopressin (AVP), administered through the oral mucosa, affect attention to emotional faces and related brain activity in healthy adults. The study will compare OT and AVP with a placebo (PLC). The main questions it aims to answer are: 1. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07338682
Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients
Phase 2
German University in Cairo
About 60 people
Started Aug 27, 2025
In plain words A Phase 2 study of L-arginine in people 60 and older, run by German University in Cairo. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 60 and older. Conditions: Cognition Disorders in Old Age; Cognitive and Behavioral Impairment.
Age >60 years
Montreal Cognitive Assessment (MoCA) test score from 10-25 (mild to moderate cognitive impairment)
The exclusion criteria are on the listing.
What it tests, as registered
L-Arginine; Placebo
Registered summary
This study aims to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Eligible participants will receive either L-arginine (6 grams once daily) or placebo, and their cognitive performance will be assessed using validated cognitive assessment tools over the study period. The participants will receive the intervention for 4 weeks and followed up every 2 weeks. The primary outcome is improvement in cognitive function, while secondary outcomes include safety, tolerability, and quality of life measures. The full summary is on the listing.
Where, as registered
No US site; Egypt (1).
RecruitingNCT05306925
An Exploratory Study of Arginine Supplementation and the Postoperative Immune REsponse
No phase
University of Liverpool
About 48 people
Started Apr 14, 2022
In plain words A study of L-arginine in people 22 weeks to 44 weeks, run by University of Liverpool. It plans to enroll about 48 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 22 weeks to 44 weeks. Conditions: Preterm; Surgery; Nutritional Deficiency; Immune System and Related Disorders.
Preterm infants born <30 weeks gestation requiring laparotomy/major bowel surgery or diagnosed with necrotising enterocolitis (Modified Bell's Stage II or higher) before discharge
Term and near term infants (born>35 weeks gestation) requiring laparotomy/major bowel surgery in the first 3 days of life (gastroschisis; major bowel atresias expected to require at least 7 days of PN)
The exclusion criteria are on the listing.
What it tests, as registered
Arginine
Registered summary
ASPIRE is a nutrition study focusing on the effect of arginine supplementation on immune function in postoperative infants. The investigators will explore the effect of current intravenous feeding (parenteral nutrition (PN)) formulations and oral arginine supplementation on blood arginine levels and the genes that are involved in body nutrition and fighting infection in babies who have had major bowel surgery or been diagnosed with necrotising enterocolitis. The full summary is on the listing.
Where, as registered
No US site; United Kingdom (2).
Not yet recruitingNCT07718373
Early Postoperative L-arginine and Acute Kidney Injury After Cardiac Surgery
Observational
Xijing Hospital
About 5,000 people
Starts Jul 20, 2026 (estimated)
In plain words An observational study of L-arginine in people 18 and older, run by Xijing Hospital. It plans to enroll about 5,000 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Acute Kidney Injury.
What it tests, as registered
L-arginine
Registered summary
Acute kidney injury (AKI) is common after cardiac surgery, yet effective protective strategies remain limited. L-arginine is the substrate for endogenous nitric oxide (NO) synthesis and may improve renal perfusion and endothelial function. investigators emulated a target trial to evaluate whether early perioperative L-arginine was associated with a lower risk of AKI after cardiac surgery.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07394270
Effect of Add-on L-Arginine Therapy on Heart Failure Patients
Phase 2
German University in Cairo
About 200 people
Starts Feb 2026 (estimated)
In plain words A Phase 2 study of L-arginine in people 19 and older, run by German University in Cairo. It plans to enroll about 200 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 19 and older. Conditions: Heart Failure.
Patients with EF <40%
eGFR >30 mL/min/1.73 m2
Stable patients
Capable and willing to provide written consent
The exclusion criteria are on the listing.
What it tests, as registered
L-Arginine Powder; Placebo
Registered summary
Heart failure is considered one of the greatest challenges globally. There are various treatment strategies for heart failure. L-Arginine is an amino acid that was found to have beneficial effect on vasculature. This study aims to study the benefits and side effects of using L-arginine on the patients with ejection fraction \<40%
Where, as registered
No US site; Egypt (1).
Not yet recruitingNCT07755124
Dietary Arginine Deprivation Combined With Chemoradiotherapy for Neoadjuvant Treatment of Rectal Cancer: A Randomized Controlled Trial
Phase 1 and 2
West China Hospital
About 140 people
Starts Aug 14, 2026 (estimated)
In plain words A Phase 1 and 2 study of L-arginine in people 18 to 80, run by West China Hospital. It plans to enroll about 140 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Rectal Neoplasms.
Signed written informed consent prior to any study-related procedures.
Male or female, aged 18 to 80 years.
Locally advanced mid-low rectal cancer staged as cT3, cT4, or node-positive by rectal MRI.
ECOG performance status 0-1.
16 more inclusion criteria and the exclusion criteria are on the listing.
This study evaluates whether an arginine-free diet combined with chemoradiotherapy can improve treatment outcomes in patients with locally advanced rectal cancer. Our previous study showed that an arginine-free diet is safe and may boost the body's immune response against tumors. The study has two phases. The first phase (6 patients) tests the safety of the diet. The second phase (134 patients) randomly assigns participants to receive either the arginine-free diet plus standard chemoradiotherapy or standard chemoradiotherapy alone. The full summary is on the listing.